On November 5, 2025 Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, reported a strategic collaboration with Johnson & Johnson* to advance the discovery of novel in vivo CAR-T cell therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration aims to develop next-generation in vivo CAR-T cell therapies with Kelonia’s proprietary iGPS (in vivo Gene Placement System) platform for Johnson & Johnson’s targets of interest. In vivo CAR-T cell therapies represent a potentially transformative approach that aims to make these medicines more accessible and reduce the burden of treatment for patients.

"This collaboration reflects a growing momentum and is a powerful validation of Kelonia’s iGPS platform and its potential to define the future of in vivo CAR-T therapy," said Kevin Friedman, Ph.D., Chief Executive Officer and Founder of Kelonia. "By leveraging our in vivo gene delivery technology through this strategic partnership, we’re taking a major step on our journey toward democratizing CAR-T cell therapies."

(Press release, Kelonia Therapeutics, NOV 5, 2025, View Source [SID1234664928])